Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.

Related Articles

Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.

Gynecol Oncol. 2018 11;151(2):243-249

Authors: Liu Y, Weber Z, San Lucas FA, Deshpande A, Jakubek YA, Sulaiman R, Fagerness M, Flier N, Sulaiman J, Davis CM, Fowler J, Starks D, Rojas-Espaillat L, Lazar AJ, Davies GE, Ehli EA, Scheet P

Abstract
OBJECTIVE: Uterine carcinosarcoma (UCS) is a rare and aggressive form of uterine cancer. It is bi-phasic, exhibiting histological features of both malignant epithelial (carcinoma) and mesenchymal (sarcoma) elements, reflected in ambiguity in accepted treatment guidelines. We sought to study the genomic and transcriptomic profiles of these elements individually to gain further insights into the development of these tumors.
METHODS: We macro-dissected carcinomatous, sarcomatous, and normal tissues from formalin fixed paraffin embedded uterine samples of 10 UCS patients. Single nucleotide polymorphism microarrays, targeted DNA sequencing and whole-transcriptome RNA-sequencing were performed. Somatic chromosomal alterations (SCAs), point mutation and gene expression profiles were compared between carcinomatous and sarcomatous components.
RESULTS: In addition to TP53, other recurrently mutated genes harboring putative driver or loss-of-function mutations included PTEN, FBXW7, FGFR2, KRAS, PIK3CA and CTNNB1, genes known to be involved in UCS. Intra-patient somatic mutation and SCA profiles were highly similar between paired carcinoma and sarcoma samples. An epithelial-mesenchymal transition (EMT) signature tended to differentiate components, with EMT-like status more common in advanced-stage patients exhibiting higher inter-component SCA heterogeneity.
CONCLUSIONS: From DNA analysis, our results indicate a monoclonal disease origin for this cohort. Yet expression-derived EMT statuses of the carcinomatous and sarcomatous components were often discrepant, and advanced cases displayed greater genomic heterogeneity. Therefore, separately-profiled components of UCS tumors may better inform disease progression or potential.

PMID: 30194005 [PubMed - indexed for MEDLINE]

from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2SgxObL